In what cardiologists are calling a potential paradigm shift, researchers at Stanford University School of Medicine have identified a naturally occurring protein — dubbed PROTECT-1 — that appears to regenerate damaged cardiac muscle tissue with remarkable speed in animal models. Human trials are expected to begin in early 2026.
The Science Behind PROTECT-1
The protein was discovered during a genome-wide association study examining long-lived individuals with no history of cardiovascular disease. It was found in unusually high concentrations in the blood of centenarians from Sardinia, Italy — a Blue Zone known for exceptional longevity.
When PROTECT-1 was administered intravenously to mice with induced myocardial infarction, researchers observed a 73% restoration of cardiac function within 72 hours. The mechanism appears to involve the activation of dormant cardiac stem cells.
Clinical Pathway
The FDA granted PROTECT-1 Fast Track designation in October 2025. Phase I trials will assess safety and dosing in 120 patients with stable heart failure. If successful, Phase II trials could begin as early as 2027.
"We have been searching for a molecule like this for decades. The natural occurrence of PROTECT-1 in exceptionally healthy populations gives us confidence it will have a favorable safety profile in humans." — Dr. Michael Torres, Stanford Cardiovascular Research Center
Broader Implications
Heart disease remains the leading cause of death globally, responsible for approximately 18 million deaths annually. An effective regenerative therapy could dramatically reduce this burden and reduce the need for heart transplants.
